CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from Central South China

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Huang, Feng Mao ^a,b   Chen, Han Chun ^a   Khan, Md Asaduzzaman ^a   Yang, Fu Lan ^a   Wan, Xin Xing ^a   Xu, Ai Hua ^a   Ou Yang, Fang Dan ^a   Zhang, Dian Zheng ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

Chinese population; Cytochrome P450 enzymes; Genetic polymorphism; Lung cancer susceptibility; Multifactor dimensionality reduction

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; GENOMIC DNA; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; CYP1A1 PROTEIN, HUMAN; TUMOR MARKER; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ISOLATION; ENZYME POLYMORPHISM; FEMALE; GENE INTERACTION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WILD TYPE; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; MIDDLE AGED;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CHINA; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84874605254     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0521-z     Document Type: Article

References (21)

1. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol. 2006;14:21-33.
2. Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, Ou-Yang FD, Zhang DZ. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumor Biol. 2011;32:215-22.
3. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 2008;21:70-83.
4. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211-4.
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
6. Chen HC, Cao YF, Hu WX, Liu XF, Liu QX, Zhang J, Liu J. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China. Dis Markers. 2006;22:141-52.
7. Davis LG, Dibner MD, Battey JF. Preparation of DNA from eukaryotic cells. In: Davis LG, Dibner MD, Battey JF, editors. Basic methods in molecular biology. New York: Elsevier; 1986. p. 42-50.
8. Oscarson M, McLellan RA, Gullstén H, Yue QY, Lang MA, Bernal ML, Sinues B, Hirvonen A, Raunio H, Pelkonen O, Ingelman-Sundberg M. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999;448:105-10.
9. Tamaki Y, Arai T, Sugimura H, Sasaki T, Honda M, Muroi Y, Matsubara Y, Kanno S, Ishikawa M, Hirasawa N, Hiratsuka M. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet. 2011;26:516-22.
10. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003;19:376-82.
11. Hatagima A. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cad Saude Publica. 2002;18:357-77.
12. Beresford AP. CYP1A1: friend or foe? Drug Metab Rev. 1993;25:503-17.
13. Song N, Tan W, Xing D, Lin D. CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis. 2001;22:11-6.
14. Kamataki T, Fujita K, Nakayama K, Yamazaki Y, Miyamoto M, Ariyoshi N. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metab Rev. 2002;34:667-76.
15. Thuerauf N, Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci. 2006;256:287-93.
16. Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L, McLachlan RE, Yang IA, Bowman RV, Fong KM. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur Respir J. 2010;35:152-9.
17. Shah PP, Singh AP, Singh M, Mathur N, Pant MC, Mishra BN, Parmar D. Interaction of cytochrome P4501A1 genotypes with other risk factors and susceptibility to lung cancer. Mutat Res. 2008;639:1-10.
18. Islam MS, Ahmed MU, Bin Sayeed MS, Al Maruf A, Mostofa AG, Akram Hussain SM, Kabir Y, Daly AK, Hasnat A. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta. 2013;416:11-9.
19. Ji YN, Wang Q, Lin XQ, Suo LJ. CYP1A1 MspI polymorphisms and lung cancer risk: an updated meta-analysis involving 20,209 subjects. Cytokine. 2012;59:324-34.
20. Wang N, Wu Y, Zhou X, Wu Y. Association between genetic polymorphism of metabolizing enzymes and DNA repairing enzymes and the susceptibility of lung cancer in Henan population. Wei Sheng Yan Jiu. 2012;41:251-6.
21. Gu Y, Zhang S, Lai B, Zhan X, Zhang Y. Frequency of CYP2A6 gene deletion and its relation to risk of lung cancer. Zhongguo Fei Ai Za Zhi. 2005;8:297-9.